Visen Pharmaceuticals, An Innovative Biopharmaceutical Company Focused On Endocrine Diseases, Announced Positive Top-Line Results From Its Pivotal Phase 3 Trial, A Randomized, Open-Label, Active-Controlled Trial That Compared Lonapegsomatropin (Transcon Hgh), A Once-Weekly Administered Long-Acting Drug That Delivers Unmodified Growth Hormone, To A Daily Human Growth Hormone (Hgh) In Children With Growth Hormone Deficiency (Ghd) In China.
